Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

D. W. Hommes, T. L. Mikhajlova, S. Stoinov, D. Štimac, B. Vucelic, J. Lonovics, M. Zákuciová, G. D'Haens, G. Van Assche, S. Ba, S. Lee, T. Pearce

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Introduction: Interferon γ is a potent proinflammatory cytokine implicated in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe CD. Methods: A total of 133 patients with Crohn's disease activity index (CDAI) scores between 250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg. Forty two patients received one dose and 91 patients received two doses on days 0 and 28. Investigators and patients were unaware of assignment. Study end points were safety, clinical response (decrease in CDAI of 100 points or more), and remission (CDAI ≤ 150). Results: There was no statistically significant difference in the primary end point of the study (clinical response) between the fontolizumab and placebo groups after a single dose at day 28. However, patients receiving two doses of fontolizumab demonstrated doubling in response rate at day 56 compared with placebo: 32% (9/28) versus 69% (22/32, p = 0.02) and 67% (21/31, p = 0.03) for the placebo, and 4 and 10 mg/kg fontolizumab groups, respectively. Stratification according to elevated baseline C reactive protein levels resulted in a decreased placebo response and pronounced differences in clinical benefit. Two grade 3 adverse events were reported and were considered to be related to CD. One death (during sleep) and one serious adverse event (an elective hospitalisation) occurred, both considered unrelated. Conclusion: Treating active CD with fontolizumab was well tolerated and resulted in increased rates of clinical response and remission compared with placebo.

Original languageEnglish
Pages (from-to)1131-1137
Number of pages7
JournalGut
Volume55
Issue number8
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Antibodies, Monoclonal, Humanized
Crohn Disease
Interferons
Anti-Idiotypic Antibodies
Safety
Placebos
fontolizumab
C-Reactive Protein
Sleep
Hospitalization
Research Personnel
Cytokines
Inflammation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. / Hommes, D. W.; Mikhajlova, T. L.; Stoinov, S.; Štimac, D.; Vucelic, B.; Lonovics, J.; Zákuciová, M.; D'Haens, G.; Van Assche, G.; Ba, S.; Lee, S.; Pearce, T.

In: Gut, Vol. 55, No. 8, 08.2006, p. 1131-1137.

Research output: Contribution to journalArticle

Hommes, DW, Mikhajlova, TL, Stoinov, S, Štimac, D, Vucelic, B, Lonovics, J, Zákuciová, M, D'Haens, G, Van Assche, G, Ba, S, Lee, S & Pearce, T 2006, 'Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease', Gut, vol. 55, no. 8, pp. 1131-1137. https://doi.org/10.1136/gut.2005.079392
Hommes, D. W. ; Mikhajlova, T. L. ; Stoinov, S. ; Štimac, D. ; Vucelic, B. ; Lonovics, J. ; Zákuciová, M. ; D'Haens, G. ; Van Assche, G. ; Ba, S. ; Lee, S. ; Pearce, T. / Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. In: Gut. 2006 ; Vol. 55, No. 8. pp. 1131-1137.
@article{6c8b59b7b179473eb120dfd62361cea5,
title = "Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease",
abstract = "Introduction: Interferon γ is a potent proinflammatory cytokine implicated in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe CD. Methods: A total of 133 patients with Crohn's disease activity index (CDAI) scores between 250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg. Forty two patients received one dose and 91 patients received two doses on days 0 and 28. Investigators and patients were unaware of assignment. Study end points were safety, clinical response (decrease in CDAI of 100 points or more), and remission (CDAI ≤ 150). Results: There was no statistically significant difference in the primary end point of the study (clinical response) between the fontolizumab and placebo groups after a single dose at day 28. However, patients receiving two doses of fontolizumab demonstrated doubling in response rate at day 56 compared with placebo: 32{\%} (9/28) versus 69{\%} (22/32, p = 0.02) and 67{\%} (21/31, p = 0.03) for the placebo, and 4 and 10 mg/kg fontolizumab groups, respectively. Stratification according to elevated baseline C reactive protein levels resulted in a decreased placebo response and pronounced differences in clinical benefit. Two grade 3 adverse events were reported and were considered to be related to CD. One death (during sleep) and one serious adverse event (an elective hospitalisation) occurred, both considered unrelated. Conclusion: Treating active CD with fontolizumab was well tolerated and resulted in increased rates of clinical response and remission compared with placebo.",
author = "Hommes, {D. W.} and Mikhajlova, {T. L.} and S. Stoinov and D. Štimac and B. Vucelic and J. Lonovics and M. Z{\'a}kuciov{\'a} and G. D'Haens and {Van Assche}, G. and S. Ba and S. Lee and T. Pearce",
year = "2006",
month = "8",
doi = "10.1136/gut.2005.079392",
language = "English",
volume = "55",
pages = "1131--1137",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

AU - Hommes, D. W.

AU - Mikhajlova, T. L.

AU - Stoinov, S.

AU - Štimac, D.

AU - Vucelic, B.

AU - Lonovics, J.

AU - Zákuciová, M.

AU - D'Haens, G.

AU - Van Assche, G.

AU - Ba, S.

AU - Lee, S.

AU - Pearce, T.

PY - 2006/8

Y1 - 2006/8

N2 - Introduction: Interferon γ is a potent proinflammatory cytokine implicated in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe CD. Methods: A total of 133 patients with Crohn's disease activity index (CDAI) scores between 250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg. Forty two patients received one dose and 91 patients received two doses on days 0 and 28. Investigators and patients were unaware of assignment. Study end points were safety, clinical response (decrease in CDAI of 100 points or more), and remission (CDAI ≤ 150). Results: There was no statistically significant difference in the primary end point of the study (clinical response) between the fontolizumab and placebo groups after a single dose at day 28. However, patients receiving two doses of fontolizumab demonstrated doubling in response rate at day 56 compared with placebo: 32% (9/28) versus 69% (22/32, p = 0.02) and 67% (21/31, p = 0.03) for the placebo, and 4 and 10 mg/kg fontolizumab groups, respectively. Stratification according to elevated baseline C reactive protein levels resulted in a decreased placebo response and pronounced differences in clinical benefit. Two grade 3 adverse events were reported and were considered to be related to CD. One death (during sleep) and one serious adverse event (an elective hospitalisation) occurred, both considered unrelated. Conclusion: Treating active CD with fontolizumab was well tolerated and resulted in increased rates of clinical response and remission compared with placebo.

AB - Introduction: Interferon γ is a potent proinflammatory cytokine implicated in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe CD. Methods: A total of 133 patients with Crohn's disease activity index (CDAI) scores between 250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg. Forty two patients received one dose and 91 patients received two doses on days 0 and 28. Investigators and patients were unaware of assignment. Study end points were safety, clinical response (decrease in CDAI of 100 points or more), and remission (CDAI ≤ 150). Results: There was no statistically significant difference in the primary end point of the study (clinical response) between the fontolizumab and placebo groups after a single dose at day 28. However, patients receiving two doses of fontolizumab demonstrated doubling in response rate at day 56 compared with placebo: 32% (9/28) versus 69% (22/32, p = 0.02) and 67% (21/31, p = 0.03) for the placebo, and 4 and 10 mg/kg fontolizumab groups, respectively. Stratification according to elevated baseline C reactive protein levels resulted in a decreased placebo response and pronounced differences in clinical benefit. Two grade 3 adverse events were reported and were considered to be related to CD. One death (during sleep) and one serious adverse event (an elective hospitalisation) occurred, both considered unrelated. Conclusion: Treating active CD with fontolizumab was well tolerated and resulted in increased rates of clinical response and remission compared with placebo.

UR - http://www.scopus.com/inward/record.url?scp=33746176176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746176176&partnerID=8YFLogxK

U2 - 10.1136/gut.2005.079392

DO - 10.1136/gut.2005.079392

M3 - Article

VL - 55

SP - 1131

EP - 1137

JO - Gut

JF - Gut

SN - 0017-5749

IS - 8

ER -